Scholar Rock Grants Inducement Equity Awards to New Employees Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to developing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases influenced by protein growth factors, has announced the…
The “Powering Milwaukee Forward” initiative is set to enhance access to essential services and maternal healthcare in vulnerable communities across Milwaukee. Launched by GE HealthCare (Nasdaq: GEHC), the GE HealthCare Foundation, and the Charles Antetokounmpo Family Foundation (CAFF), this philanthropic…
Ferring Pharmaceuticals Showcases Commitment to Advancing Fertility Care at 2024 ASRM Congress Ferring Pharmaceuticals will present new data from four abstracts at the 2024 American Society for Reproductive Medicine (ASRM) Congress, taking place from October 19-23 in Denver, Colorado, and…
Successful Cyclotron Irradiation of Ra-226 Paves the Way for Actineer’s Large-Scale Ac-225 Production for Cancer Treatments Actineer, the joint venture between ITM and Canadian Nuclear Laboratories (CNL) Ltd., has achieved a significant milestone by successfully producing Actinium-225 (Ac-225) through the…
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced that five of its abstracts have been accepted for e-Poster presentations at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), scheduled to be held in Boston,…
Nordic Pharma, a subsidiary of Nordic Group BV, is advancing the U.S. introduction of LACRIFILL® Canalicular Gel, a novel therapy for dry eye, during the 2024 American Academy of Ophthalmology (AAO) meeting. Following its U.S. launch in April, LACRIFILL will…
Xaira Therapeutics Appoints Dr. Debbie Law as Chief Scientific Officer and Julia Tran as Chief People Officer Xaira Therapeutics, an integrated biotechnology firm focused on leveraging AI to transform drug discovery and development, has announced the appointments of Dr. Debbie…
Alnylam Pharmaceuticals, Inc. has submitted a Type II variation application to the European Medicines Agency (EMA) for vutrisiran, an investigational RNA interference (RNAi) therapy aimed at treating ATTR amyloidosis with cardiomyopathy (ATTR-CM). This application is based on the positive results…
Komodo Health Unveils National Drug Projections for Real-Time Prescription Insights Komodo Health has launched its new product, National Drug Projections, offering a comprehensive view of prescription trends across the U.S. The solution provides real-time insights into pharmacy and medical benefit…
ModMed Empowers Ophthalmology Practices with Innovative Solutions at AAO 2024 ModMed® is excited to announce its participation in the American Academy of Ophthalmology (AAO) 2024 conference, taking place from October 19-21 in Chicago. At this year’s event, ModMed will showcase…
DNA Script Appoints Marc Montserrat as CEO, Thomas Ybert Transitions to Chief Scientific Officer DNA Script, a leader in enzymatic DNA synthesis, has appointed Marc Montserrat as its new Chief Executive Officer, while founding CEO Thomas Ybert, PhD, will shift…
HeartBeam Appoints Robert Eno as CEO, Focused on U.S. Commercialization Industry leader brings extensive experience in developing go-to-market strategies for breakthrough products and driving growth HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company dedicated to transforming cardiac care, has announced…
